Business
Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
DALLAS, May 14, 2026--Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
About this update from Lantern Pharma Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/63ad0e4015444eec83287289e8bca28f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6kHoxy239unfnYNDUZ86aA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MA--/https://media.zenfs.com/en/business-wire.com/63ad0e4015444eec83287289e8bca28f","width":480,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/mLlHhJJnxTYHmBKeizf8_w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTY0MA--/https://media.zenfs.com/en/business-wire.com/63ad0e4015444eec83287289e8bca28f","width":480,"height":480}},"lazy":false},{"type":"text","content":"$4.4 million upfront with up to an additional $4.85 million of potential aggregate gross proceeds upon the exercise in full of the warrants","length":139,"tagName":"p","attribs":{}},{"type":"text","content":"Offering priced at the closing price with unregistered warrants exercisable at a 10% premium to the close and non-exercisable for the first six months","length":150,"tagName":"p","attribs":{}},{"type":"text","content":"DALLAS, May 14, 2026--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN) ("Lantern" or the "Company"), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and machine learning platforms with multiple clinical stage drug programs, today announced the closing of its previously announced registered direct offering of 2,135,923 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $2.06 per share (or pre-funded warrant in lieu thereof). In addition, in a concurrent private placement, the Company issued unregistered warrants to purchase up to 2,135,923 shares of common stock. The warrants have an exercise price of $2.27 per share, are exercisable six months following the initial issuance date, and will expire five years following the initial exercise date.","length":902,"tagName":"p"},{"type":"text","content":"Rodman & Renshaw LLC acted as the exclusive placement agent for the offering.","length":81,"tagName":"p"},{"type":"text","content":"The aggregate gross proceeds to the Company from the offering were approximately $4.4 million, before deducting the placement ...